Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial
暂无分享，去创建一个
N. Kucher | G. Colucci | M. Schindewolf | R. Bingisser | S. Stortecky | T. Rosemann | B. Hasse | H. Spechbach | D. Duerschmied | C. Nickel | F. Glauser | C. Kessler | B. Gerber | S. Konstantinides | T. Sebastian | S. Barco | M. Righini | M. Blondon | H. Robert-Ebadi | L. Hobohm | N. Gauchel | D. Spirk | Andreas Götschi | P. Biever | C. Olivier | D. Voci | F. Mach | U. Held | A. Frenk | Alexandru Grigorean | C. Leeger | Eliane Probst | R. Spescha | U. Held | M. Rueegg | Lukas Vaisnora | Andrea Götschi | M. Cittone | Yulia Butscheid | N. Simon | D. Becker | D. Gjermeni | F. Johner | Evy Micieli | Gabor Forgo | François Mach | Jeannette Busch | I. Arnold | Silvia Ulrich | Stefano Davide Ulrike Tim Roland Giuseppe Daniel André Ber Barco Voci Held Sebastian Bingisser Coluc | Stéphanie Roth Zetzsche | G. Vatsakis | D. Keller Lang | S. Rampini Speck | Arnaud Kuenzi